Re: Illicit opioid use and its key characteristics: a select overview and evidence from a Canadian multisite cohort of illicit opioid users.
Oyemade
Adegboyega
A
D002047:Buprenorphine / Q000627:therapeutic use*; D002170:Canada; D015331:Cohort Studies; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D006801:Humans; D013287:Illicit Drugs; D008691:Methadone / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D009294:Narcotics / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000175:diagnosis / Q000523:psychology / Q000534:rehabilitation*; D010349:Patient Compliance
D003692:Delayed-Action Preparations; D013287:Illicit Drugs; D009294:Narcotics; D002047:Buprenorphine; D008691:Methadone